Société Arcturus Therapeutics Ltd Nasdaq
Actions
IL0011280240
Recherche biotechnologique et médicale
Métier
Ventes par activité
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Nucleic Acid-focused Technology
100,0
%
| 206 | 100,0 % | 167 | 100,0 % | -19,03% |
Ventes par région
USD en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 206 | 100,0 % | 167 | 100,0 % | -19,03% |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Joseph Payne
CEO | Chief Executive Officer | 52 | 01/03/13 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 01/01/19 |
Chief Operating Officer | 45 | 01/01/13 | |
Chief Tech/Sci/R&D Officer | 68 | 01/03/23 | |
Neda Safarzadeh
IRC | Investor Relations Contact | - | - |
Lance Kurata
LAW | General Counsel | 54 | 10/08/20 |
Kevin T. Skol
PRN | Corporate Officer/Principal | - | 01/01/02 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Edward W. Holmes
BRD | Director/Board Member | 83 | 01/09/19 |
James F. Barlow
BRD | Director/Board Member | 65 | 27/05/18 |
Peter Farrell
CHM | Chairman | 81 | 27/05/18 |
Andrew Sassine
DFI | Director of Finance/CFO | 59 | 01/01/19 |
Magda Marquet
BRD | Director/Board Member | 65 | 27/05/18 |
Jing Marantz
BRD | Director/Board Member | 59 | 07/12/21 |
Joseph Payne
CEO | Chief Executive Officer | 52 | 01/03/13 |
John Markels
BRD | Director/Board Member | 58 | 08/12/22 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 26 931 826 | 24 577 248 ( 91,26 %) | 0 | 91,26 % |
Coordonnées société
Arcturus Therapeutics Holdings, Inc.
10628 Science Center Drive Suite 250
92121, San Diego
+
http://www.arcturusrx.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+29,77% | 49,46 Md | |
+1,00% | 42,58 Md | |
+49,56% | 42,49 Md | |
-5,26% | 29,09 Md | |
+13,68% | 26,61 Md | |
-22,99% | 18,64 Md | |
+8,22% | 13,16 Md | |
+32,41% | 12,55 Md | |
+24,01% | 12,1 Md |